Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) EBIT (2016 - 2025)

Fate Therapeutics (FATE) has disclosed EBIT for 14 consecutive years, with -$34.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 43.77% year-over-year to -$34.7 million, compared with a TTM value of -$147.7 million through Dec 2025, up 29.76%, and an annual FY2025 reading of -$147.7 million, up 29.76% over the prior year.
  • EBIT was -$34.7 million for Q4 2025 at Fate Therapeutics, roughly flat from -$34.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$28.6 million in Q1 2023 and bottomed at -$86.4 million in Q3 2022.
  • Average EBIT over 5 years is -$53.7 million, with a median of -$51.2 million recorded in 2023.
  • The sharpest move saw EBIT plummeted 107.74% in 2021, then skyrocketed 61.6% in 2023.
  • Year by year, EBIT stood at -$69.4 million in 2021, then rose by 7.15% to -$64.4 million in 2022, then increased by 25.37% to -$48.1 million in 2023, then decreased by 28.44% to -$61.7 million in 2024, then soared by 43.77% to -$34.7 million in 2025.
  • Business Quant data shows EBIT for FATE at -$34.7 million in Q4 2025, -$34.7 million in Q3 2025, and -$37.0 million in Q2 2025.